AstraZeneca Owes $192M For Cancer Drug Rights, Rival Says
AstraZeneca owes $192 million for refusing to pay royalties for an Array cancer drug after entering an $8.5 billion collaboration with Merck to develop and commercialize the compound, according to a lawsuit...To view the full article, register now.
Already a subscriber? Click here to view full article